The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).

The present invention is directed to PVRIG polypeptides and their uses.

A single-domain antibody or an antigen-binding fragment thereof to Senecavirus A, the single-domain antibody or the antigen-binding fragment thereof being selected from 52 amino acid sequence groups, and each of the 52 amino acid sequence groups including a first variable domain of heavy chain VH-CDR-1, a second variable domain of heavy chain VH-CDR-2, and a third variable domain of heavy chain VH-CDR-3. The first variable domain of heavy chain VH-CDR-1 has an amino acid sequence represented by one of SEQ ID NO: 1-SEQ ID NO: 52. The second variable domain of heavy chain VH-CDR-2 has an amino acid sequence represented by one of SEQ ID NO: 53-SEQ ID NO: 104. The third variable domain of heavy chain VH-CDR-3 has an amino acid sequence represented by one of SEQ ID NO: 105-SEQ ID NO: 156.

The present invention relates to immunoglobulin yolk (IgY) against coxsackievirus A16 and/or enterovirus A71 and its preparation and uses thereof.

The present disclosure is directed to human and engineered antibodies and fragments thereof binding to enterovirus D68 (EV-D68), engineered cells producing the same, and of using the antibodies and fragments thereof in methods for both diagnosing and treating EV-D68 infections. Also disclosed are vaccine formulations comprising one of more of the antibody and fragments thereof, as well as vectors encoding the same.

The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).